The abstract is read at the publisher; the summary is JClub's.
Pretreatment eGFR discordance (cystatin C eGFR ≥30% lower than creatinine eGFR) is linked to higher AKI-or-death risk after allogeneic HSCT, with OR 1.75 (95% CI 1.03–3.02).
- Why it matters: Kidney function measured by creatinine versus cystatin C can disagree, and this mismatch may signal vulnerability to complications after hematopoietic stem cell transplantation or adoptive T-cell therapy.
- What they did: In a multicenter adult cohort, paired creatinine and cystatin C values within 30 days before conditioning or lymphodepleting chemotherapy defined discordance; outcomes were AKI (≥50% creatinine rise or KRT) or death by 90 days, analyzed with multivariable logistic regression and cause-specific Cox models with inverse probability weighting.
- The result: Discordance also predicted slower platelet engraftment after HSCT and prolonged cytopenia after adoptive T-cell therapy, but the AKI-or-death association was attenuated after adjusting for eGFR cr-cys.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.